On Friday 05/23/2025 the closing price of the ADMA Biologics Inc share was $20.16 on BTT.
Compared to the opening price on Friday 05/23/2025 on BTT of $20.09, this is a gain of 0.35%.
ADMA Biologics Inc's market capitalization is $4.02 B by 238.73 M shares outstanding.
Is ADMA Biologics stock a Buy, Sell or Hold?
ADMA Biologics stock has received a consensus rating of buy. The average rating score is and is based on 16 buy ratings, 3 hold ratings, and 0 sell ratings.What was the 52-week low for ADMA Biologics stock?
The low in the last 52 weeks of ADMA Biologics stock was 9.38. According to the current price, ADMA Biologics is 217.70% away from the 52-week low.What was the 52-week high for ADMA Biologics stock?
The high in the last 52 weeks of ADMA Biologics stock was 25.65. According to the current price, ADMA Biologics is 79.61% away from the 52-week high.What are analysts forecasts for ADMA Biologics stock?
The 19 analysts offering price forecasts for ADMA Biologics have a median target of 10.66, with a high estimate of 32.00 and a low estimate of 5.00. The median estimate represents a 191.60 difference from the last price of 20.42.ADMA Biologics Stock Snapshot
17.34
Bid
100.00
Bid Size
22.96
Ask
100.00
Ask Size
5/23/2025
Date
3:59 PM
Time
45,043.00
Volume
20.16
Prev. Close
20.09
Open
4.87 B
Market Cap in USD
238.73 M
Number of Shares
238.73 M
Total Number of Shares
20.00
Day Low
20.45
Day High
20.42
9.38
52 Week Low
25.65
52 Week High
20.42
0.00
Dividend in USD
0.00
Dividend Yield
21.11
P/E Ratio
96.51
Free Float in %
0.85
EPS in USD
1.48
Book Value per Share in USD
0.49
Cash Flow per Share in USD
ADMA Biologics News More News
Historical Prices for ADMA Biologics
| Date | Open | Close | Daily High | Daily Low |
|---|
Price change over selected period:
0%
0
ADMA Biologics Analyst Data
Total Analysts: 19
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price
*Price Target
Lowest: 5.00
Median: 10.66
Highest: 32.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.
ADMA Biologics Analyst Opinions
- All
- Buy
- Hold
- Sell
| Date | Analyst | Rating | Price | |||
|---|---|---|---|---|---|---|
| 05/08/25 | Raymond James Financial, Inc. | Maintained Buy | $32 | |||
| 03/04/25 | Cantor Fitzgerald | Maintained Buy | $25 | |||
| 07/09/24 | Cantor Fitzgerald | Maintained Buy | $15 | |||
| 06/20/24 | Mizuho | Maintained Buy | $14 | |||
| 05/10/24 | Raymond James Financial, Inc. | Maintained Buy | $10 | |||
| 05/10/24 | Cantor Fitzgerald | Maintained Buy | $10 | |||
| 05/10/24 | H.C. Wainwright & Co. | Maintained Buy | $10 | |||
| 05/10/24 | Mizuho | Maintained Buy | $12 | |||
| 03/26/24 | H.C. Wainwright & Co. | Maintained Buy | $7.5 | |||
| 03/01/24 | Mizuho | Maintained Buy | $10 | |||
| 02/29/24 | Cantor Fitzgerald | Maintained Buy | $8 | |||
| 02/29/24 | H.C. Wainwright & Co. | Maintained Buy | $6 | |||
| 01/22/24 | Mizuho | Maintained Buy | $9 | |||
| 01/09/24 | H.C. Wainwright & Co. | Maintained Buy | $6 | |||
| 12/19/23 | Cantor Fitzgerald | Maintained Buy | $6 | |||
| 11/17/23 | H.C. Wainwright & Co. | Maintained Buy | $5 | |||
| 08/10/23 | Cantor Fitzgerald | Maintained Buy | $6 | |||
| 08/10/23 | Raymond James Financial, Inc. | Maintained Buy | $6 | |||
| 08/10/23 | H.C. Wainwright & Co. | Maintained Buy | $5 |
ADMA Biologics Estimates* in USD
| 2025 | 2026 | 2027 | 2028 | 2029 | |
|---|---|---|---|---|---|
| Revenue | 508 | 641 | 822 | 972 | 1,097 |
| Dividend | - | - | - | - | - |
| Dividend Yield (in %) | - | - | - | - | - |
| EPS | 0.64 | 0.98 | 1.32 | 1.63 | 1.92 |
| P/E Ratio | 31.74 | 20.91 | 15.51 | 12.53 | 10.64 |
| EBIT | 202 | 304 | 409 | 504 | 592 |
| EBITDA | 237 | 346 | 440 | 544 | 666 |
| Net Profit | 158 | 239 | 325 | 404 | 477 |
| Net Profit Adjusted | 148 | 236 | 297 | 364 | 452 |
| Pre-Tax Profit | 200 | 304 | 413 | 514 | 608 |
| Pre-Tax Profit Reported | - | - | - | - | - |
| EPS (Non-GAAP) ex. SOE | 0.66 | 0.99 | 1.33 | 1.60 | 1.83 |
| EPS (GAAP) | 0.64 | 0.98 | 1.13 | 1.60 | 1.83 |
| Gross Income | 289 | 397 | 501 | 614 | 743 |
| Cash Flow from Investing | -16 | -13 | -13 | -13 | -13 |
| Cash Flow from Operations | 128 | 256 | 346 | 454 | 558 |
| Cash Flow from Financing | -7 | - | -75 | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
| Free Cash Flow per Share | - | - | - | - | - |
| Book Value per Share | - | - | - | - | - |
| Net Debt | - | - | - | - | - |
| Research & Development Exp. | 3 | 4 | 5 | 6 | 7 |
| Capital Expenditure | 16 | 13 | 13 | 13 | 13 |
| Selling, General & Admin. Exp. | 83 | 83 | 91 | 99 | 107 |
| Shareholder’s Equity | 516 | 779 | 1,133 | 1,593 | 2,158 |
| Total Assets | 660 | 939 | 1,237 | 1,715 | 2,298 |
|
Previous Quarter ending 03/31/25 |
Current Quarter ending 06/30/25 |
Next Quarter ending 09/30/25 |
Current Year ending 12/31/25 |
Next Year ending 12/31/26 |
|
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | - | 3 | 3 | 3 | 3 |
| Average Estimate | - | 0.153 USD | 0.180 USD | 0.643 USD | 0.977 USD |
| Year Ago | - | 0.138 USD | 0.153 USD | 0.848 USD | - |
| Publish Date | - | 8/6/2025 | 11/5/2025 | - | - |
| Revenue Estimates | |||||
| No. of Analysts | - | 3 | 3 | 3 | 3 |
| Average Estimate | - | 124 USD | 133 USD | 508 USD | 641 USD |
| Year Ago | - | 107 USD | 120 USD | 426 USD | - |
| Publish Date | - | 8/6/2025 | 11/5/2025 | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
Income Statements in Mio. USD
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Sales | 426.45 | 258.22 | 154.08 | 80.94 | 42.22 | 29.35 | 16.99 |
| Change of sales in % | 65.15 | 67.59 | 90.36 | 91.72 | 43.85 | 72.79 | -25.37 |
| Gross profit on sales | 219.17 | 88.22 | 34.55 | 0.46 | -19.79 | -11.00 | -26.05 |
| Gross profit on sales change in % | 148.44 | 155.34 | 7,444.76 | - | -79.88 | 57.78 | -84.23 |
| Operating income | 138.98 | 21.63 | -39.58 | -58.61 | -64.91 | -41.42 | -56.39 |
| Operating income change in % | 542.49 | - | 32.48 | 9.71 | -56.71 | 26.54 | -64.57 |
| Income before tax | 125.71 | -28.24 | -66.12 | -71.89 | -75.75 | -48.28 | -65.74 |
| Income before tax change in % | - | 57.29 | 8.03 | 5.10 | -56.90 | 26.56 | -50.24 |
| Income after tax | 197.67 | -28.24 | -65.90 | -71.65 | -75.75 | -48.28 | -65.74 |
| Income after tax change in % | - | 57.15 | 8.02 | 5.41 | -56.90 | 26.56 | -50.24 |
Balance Sheet in Mio. USD
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Total liabilities | 149.36 | 193.98 | 196.49 | 135.08 | 119.42 | 100.90 | 69.11 |
| Long-term liabilities per share | 0.40 | 0.64 | 0.71 | 0.53 | 0.95 | 1.46 | 1.28 |
| Equity | 349.02 | 135.21 | 151.97 | 141.17 | 88.25 | 26.19 | 19.77 |
| Equity change in % | 158.14 | -11.03 | 7.65 | 59.97 | 236.92 | 32.49 | -50.98 |
| Balance sheet total | 498.38 | 329.18 | 348.46 | 276.25 | 207.67 | 127.09 | 88.88 |
| Balance sheet total change in % | 51.40 | -5.53 | 26.14 | 33.02 | 63.41 | 43.00 | -17.72 |
Key Data in USD
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Sales per share | 1.75 | 1.15 | 0.78 | 0.58 | 0.49 | 0.54 | 0.38 |
| P/E ratio (year end quote, basic EPS) | 21.11 | - | - | - | - | - | - |
| P/E ratio (year end quote, diluted EPS) | 21.11 | - | - | - | - | - | - |
| Dividend yield in % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Equity ratio in % | 70.03 | 41.07 | 43.61 | 51.10 | 42.49 | 20.61 | 22.24 |
| Debt ratio in % | 29.97 | 58.93 | 56.39 | 48.90 | 57.51 | 79.39 | 77.76 |
ADMA Biologics Insider Activity
| Name | Date | shares traded | shares held | Price | type (sell/buy) | option |
|---|---|---|---|---|---|---|
| Grossman Adam S | 04/14/2025 | 15,000.00 | 2,061,850.00 | 21.46 | Sell | No |
| Grossman Adam S | 04/14/2025 | 6,000.00 | 2,055,850.00 | 21.46 | Sell | No |
| Grossman Adam S | 04/14/2025 | 15,000.00 | 2,076,850.00 | 5.40 | Buy | No |
| Grossman Adam S | 03/18/2025 | 6,000.00 | 2,061,850.00 | 18.92 | Sell | No |
| Grossman Adam S | 03/18/2025 | 15,000.00 | 2,067,850.00 | 18.92 | Sell | No |
| Grossman Adam S | 03/18/2025 | 15,000.00 | 2,082,850.00 | 5.40 | Buy | No |
| Kestenberg-Messina Kaitlin M. | 03/06/2025 | 3,935.00 | 509,345.00 | 17.02 | Sell | No |
| Grossman Adam S | 03/06/2025 | 29,513.00 | 2,067,850.00 | 17.02 | Sell | No |
| Kestenberg-Messina Kaitlin M. | 03/05/2025 | 8,881.00 | 513,280.00 | 16.91 | Sell | No |
| Grossman Adam S | 03/05/2025 | 56,438.00 | 2,097,363.00 | 16.91 | Sell | No |
| Grossman Adam S | 02/25/2025 | 54,867.00 | 2,153,801.00 | 15.78 | Sell | No |
| Tade Brad L. | 02/25/2025 | 5,280.00 | 256,380.00 | 15.78 | Sell | No |
| Kestenberg-Messina Kaitlin M. | 02/24/2025 | 1,855.00 | 522,161.00 | 15.44 | Sell | No |
| Grossman Adam S | 02/24/2025 | 18,018.00 | 2,208,668.00 | 15.44 | Sell | No |
| KWON YOUNG | 02/18/2025 | 10,889.00 | 252,330.00 | n/a | Sell | No |
| Grossman Adam S | 02/18/2025 | 252,022.00 | 2,226,686.00 | n/a | Buy | No |
| Kestenberg-Messina Kaitlin M. | 02/18/2025 | 77,784.00 | 524,016.00 | n/a | Buy | No |
| Guiheen Lawrence P. | 02/18/2025 | 10,889.00 | 164,830.00 | n/a | Buy | No |
| Tade Brad L. | 02/18/2025 | 62,227.00 | 261,660.00 | n/a | Buy | No |
| Grossman Jerrold B | 02/18/2025 | 10,889.00 | 478,194.00 | n/a | Buy | No |
| FINGER ALISON CECILY | 02/18/2025 | 10,889.00 | 34,929.00 | n/a | Buy | No |
| ELMS STEVE | 02/18/2025 | 10,889.00 | 87,330.00 | n/a | Buy | No |
| Salas Eduardo Rene | 02/18/2025 | 10,889.00 | 10,889.00 | n/a | Buy | No |
| Kestenberg-Messina Kaitlin M. | 01/29/2025 | 3,355.00 | 446,232.00 | 16.10 | Sell | No |
| Kestenberg-Messina Kaitlin M. | 01/29/2025 | 5,000.00 | 449,587.00 | 10.80 | Buy | No |
ADMA Biologics Dividend Calendar
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2024 | ADMA Biologics Inc | 0.00 | 0.00 | USD |
| 2023 | ADMA Biologics Inc | 0.00 | 0.00 | USD |
| 2022 | ADMA Biologics Inc | 0.00 | 0.00 | USD |
| 2021 | ADMA Biologics Inc | 0.00 | 0.00 | USD |
| 2020 | ADMA Biologics Inc | 0.00 | 0.00 | USD |
| 2019 | ADMA Biologics Inc | 0.00 | 0.00 | USD |
| 2018 | ADMA Biologics Inc | 0.00 | 0.00 | USD |
| 2017 | ADMA Biologics Inc | 0.00 | 0.00 | USD |
| 2016 | ADMA Biologics Inc | 0.00 | 0.00 | USD |
| 2015 | ADMA Biologics Inc | 0.00 | 0.00 | USD |
| 2014 | ADMA Biologics Inc | 0.00 | 0.00 | USD |
| 2013 | ADMA Biologics Inc | 0.00 | 0.00 | USD |
| 2012 | ADMA Biologics Inc | - | - | USD |
| 2011 | ADMA Biologics Inc | - | - | USD |
| 2010 | ADMA Biologics Inc | 0.00 | - | USD |
*Yield of the Respective Date
ADMA Biologics Calendar
| Event | Estimate | Info | Date |
|---|---|---|---|
| Annual General Meeting | 0.850 USD | Annual General Meeting | 06/04/2025 |
| Earnings Report | 0.153 USD | Q2 2025 Earnings Release | 08/06/2025 |
| Earnings Report | 0.180 USD | Q3 2025 Earnings Release | 11/05/2025 |
| Earnings Report | 0.200 USD | Q4 2025 Earnings Release | 03/19/2026 |
| Earnings Report | 0.240 USD | Q1 2026 Earnings Release | 05/13/2026 |
ADMA Biologics Past Events
| Event | Actual EPS | Info | Date |
|---|---|---|---|
| Earnings Report | 0.110 USD | Q1 2025 Earnings Release | 05/07/2025 |
| Earnings Report | 0.460 USD | Q4 2024 Earnings Release | 03/03/2025 |
| Earnings Report | 0.150 USD | Q3 2024 Earnings Release | 11/07/2024 |
| Earnings Report | 0.130 USD | Q2 2024 Earnings Release | 08/08/2024 |
| Annual General Meeting | -0.130 USD | Annual General Meeting | 06/04/2024 |
| Earnings Report | 0.080 USD | Q1 2024 Earnings Release | 05/09/2024 |
| Earnings Report | -0.080 USD | Q4 2023 Earnings Release | 02/28/2024 |
| Earnings Report | 0.010 USD | Q3 2023 Earnings Release | 11/08/2023 |
| Earnings Report | -0.030 USD | Q2 2023 Earnings Release | 08/09/2023 |
| Annual General Meeting | -0.330 USD | Annual General Meeting | 06/06/2023 |
| Earnings Report | -0.030 USD | Q1 2023 Earnings Release | 05/10/2023 |
| Earnings Report | -0.060 USD | Q4 2022 Earnings Release | 03/23/2023 |
| Earnings Report | -0.080 USD | Q3 2022 Earnings Release | 11/09/2022 |
| Earnings Report | -0.070 USD | Q2 2022 Earnings Release | 08/10/2022 |
| Annual General Meeting | -0.510 USD | Annual General Meeting | 06/21/2022 |
| Earnings Report | -0.130 USD | Q1 2022 Earnings Release | 05/11/2022 |
| Earnings Report | -0.090 USD | Q4 2021 Earnings Release | 03/24/2022 |
ADMA Biologics Profile
ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B.